Recent performance context for Chemed
Chemed (CHE) has drawn fresh attention after a challenging year for the stock, with negative total returns over the past year and past 3 months prompting investors to reassess the business and its current valuation.
See our latest analysis for Chemed.
With the share price at $377.57, Chemed’s recent 10.4% 1 month share price decline and 11.75% 3 month share price decline sit alongside a 38.27% 1 year total shareholder return decline. This suggests momentum has been fading rather than building.
If this hospice and services business has you rethinking where growth might come from, it could be worth widening your search to other themes using the 33 healthcare AI stocks
With Chemed trading at $377.57 and indicators such as an intrinsic discount of about 44% and a value score of 5, the key question is whether this weakness signals a potential entry point or if the market already reflects its future growth.
Most Popular Narrative: 15% Undervalued
Chemed's most followed narrative sets a fair value of $443 per share, compared to the last close at $377.57, framing the recent share price weakness very differently from the market.
The ramp-up of new Certificate of Need (CON) locations in underserved Florida counties (e.g., Pinellas and Marion) is expected to materially expand VITAS's service footprint, aligning with the continued aging U.S. population and the shift toward home-based care, both key drivers of higher patient volumes and long-term top-line revenue growth.
Investors may want to understand what sits behind that growth push in hospice, buybacks and margins, as the narrative connects revenue, earnings and valuation in a single model.
Result: Fair Value of $443 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you also need to weigh risks such as reimbursement changes at VITAS, as well as weaker residential demand and higher costs at Roto Rooter that could pressure margins.
Find out about the key risks to this Chemed narrative.
Next Steps
With mixed signals on recent performance and valuation, it helps to look at the full picture and move quickly to your own view by weighing the 3 key rewards and 1 important warning sign
Looking for more investment ideas?
If Chemed has you rethinking your portfolio, do not stop here. Widening your search across different types of opportunities can reveal ideas that better match your goals.
- Target potential mispricings by scanning companies that combine quality metrics with lower valuations using the 63 high quality undervalued stocks
- Strengthen your income stream by reviewing companies offering solid yields backed by disciplined payout profiles through the 12 dividend fortresses
- Prioritise resilience by focusing on companies with healthier balance sheets and fundamentals via the solid balance sheet and fundamentals stocks screener (39 results)
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com